Amylyx Pharmaceuticals, Inc. (AMLX)
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$144.7M
- Total assets
- $332.6M
- Market cap
- $1.5B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Cost of revenue
- $0
- Operating income
- -$153.3M
- Income tax
- $46.0K
- Net income
- -$144.7M
- EPS (basic)
- $-1.53
- EPS (diluted)
- $-1.53
Balance sheet
- Total assets
- $332.6M
- Current assets
- $323.7M
- Total liabilities
- $27.4M
- Current liabilities
- $22.7M
- Shareholders’ equity
- $305.3M
Cash flow
- Operating cash flow
- -$123.3M
- Investing cash flow
- $14.0M
- Financing cash flow
- $257.0M
- Net cash flow
- $148.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $1.5B
- EPS (diluted)
- $-1.53
- Dividend yield
- 9.46%
- Shares outstanding
- 83.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 7, 2022
Amylyx Pharmaceuticals, Inc. (AMLX) Stock Price
- Reported a net loss of $144.7M in FY2025.
- Trading 5% below its 52-week high.
- Pays a dividend yielding about 9.46% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Amylyx Pharmaceuticals, Inc..
Write a review
News about Amylyx Pharmaceuticals, Inc.
News & sentiment via Polygon.io
Amylyx Pharmaceuticals, Inc.: frequently asked questions
Is Amylyx Pharmaceuticals, Inc. an American company?
Amylyx Pharmaceuticals, Inc. is a US-based company headquartered in Cambridge, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Amylyx Pharmaceuticals, Inc. headquartered?
Amylyx Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts, United States.
Is Amylyx Pharmaceuticals, Inc. publicly traded?
Yes — Amylyx Pharmaceuticals, Inc. is a publicly traded company. Its stock trades under the ticker symbol AMLX on the NASDAQ.
What does Amylyx Pharmaceuticals, Inc. do?
Amylyx Pharmaceuticals, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
When was Amylyx Pharmaceuticals, Inc. founded?
Amylyx Pharmaceuticals, Inc. was founded in 2013.
